Earnings (Loss) per Share	9 Months Ended
Sep. 30, 2022
Earnings (Loss) per Share	NOTE 13 – Earnings (Loss) per share: Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units (“RSUs”) and performance share units (“PSUs”) during the period, net of treasury shares. In computing diluted earnings per share for the three months ended September 30, 2022 and 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans . No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share. In computing diluted loss per share for the nine months ended September 30, 2022, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. In computing diluted earnings per share for the nine months ended September 30, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans . No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share. The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended September 30, 2022, and 2021, were 1,119 million and 1,109 million shares, respectively. The weighted average diluted shares outstanding used for the fully diluted share calculations for the nine months ended September 30, 2022, and 2021, were each 1,109 million shares. Basic and diluted earnings per share were $0.05 for the three months ended September 30, 2022, compared to basic and diluted earnings per share of $0.26 for the three months ended September 30, 2021. Basic and diluted loss per share was $1.02 for the nine months ended September 30, 2022, compared to basic and diluted earnings per share of $0.52 for the nine months ended September 30, 2021.

Earnings (Loss) per Share

9 Months Ended

Sep. 30, 2022

NOTE 13 – Earnings (Loss) per share:

Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units (“RSUs”) and performance share units (“PSUs”) during the period, net of treasury shares.

In computing diluted earnings per share for the three months ended September 30, 2022 and 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and

non-vested

RSUs and PSUs granted under employee stock compensation plans

. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per

share.

In computing

diluted loss per share for the nine months ended September 30, 2022, no account was taken of the potential dilution that could occur upon the exercise of options and

non-vested

RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share.

In computing diluted earnings per share for the nine months ended September 30, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and

non-vested

RSUs and PSUs granted under employee stock compensation plans

. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share.

The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended September 30, 2022, and 2021, were 1,119 million and 1,109 million shares, respectively.

The weighted average diluted shares outstanding used for the fully diluted share calculations for the nine months ended September 30, 2022, and 2021, were each

1,109

million shares.

Basic and diluted earnings per share were $0.05 for the three months ended September 30, 2022, compared to basic and diluted earnings per share of $0.26 for the three months ended September 30, 2021. Basic and diluted loss per share was $1.02 for the nine months ended September 30, 2022, compared to basic and diluted earnings per share of $0.52 for the nine months ended September 30, 2021.